Cover image of the article: Quality by Design: A Roadmap for Quality Pharmaceutical Products

Image Credit:J Rep Pharm Sci

Quality by Design: A Roadmap for Quality Pharmaceutical Products

Authors

Mayur Ashok Chordiya1,*, Hemant Hiraman Gangurde1, Vikram Nirmal Sancheti2
1Department of Pharmaceutics, SNJB's Shriman Sureshdada Jain College of Pharmacy, Nashik, India
2Department of Pharmaceutics, Rajarshi Shahu College of Pharmacy, Buldana, Maharashtra, India
*Corresponding Author: Corresponding author: Department of Pharmaceutics, SNJB's Shriman Sureshdada Jain College of Pharmacy, Nashik, India. Email:chordiya.mayur@gmail.com

Journal of Reports in Pharmaceutical Sciences:Vol. 8, issue 2; 289-94
Published online:Dec 31, 2019
Article type:Systematic Review
How to Cite:Chordiya MA, Gangurde HH, Sancheti VN. Quality by Design: A Roadmap for Quality Pharmaceutical Products. J Rep Pharm Sci. 2019;8(2):e147415. doi: https://doi.org/10.4103/jrptps.jrptps_2_18

Abstract

Quality by design (QbD) refers to a new approach to product development that could increase efficiencies, provide regulatory relief and flexibility, and offer important business benefits throughout the product life cycle. QbD is increasingly becoming an important and widely used technique in the pharmaceutical industry. QbD can be considered to be system‑based approach to the design, development, and delivery of any product or service to a consumer. It is an approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control. Process parameters and quality attributes are identified for each unit operation. Benefits, opportunities, and steps involved in QbD of pharmaceutical products are described. The aim of pharmaceutical development is to design a quality product and its manufacturing process to consistently deliver the intended performance of the product. Quality cannot be tested into products, but quality should be built in by design. It includes the quality target product profile, critical quality attributes, and key aspects of QbD. It also gives comparison between product quality by end product testing and product quality by QbD. The foundation of QbD is ICH guidelines. Hence, if we identify the cause and effect relationship between the various inputs and responses by carefully designed experiments, we can control the quality of the product by simply controlling the inputs such as raw material specifications or process parameters. 

Highlights

Copyright

© 2019, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

5
Mar
2024
Quality by Design (QbD) Paradigm: An Integrated Multivariate Approach to Transdermal Patch System Development

Quality by Design (QbD) Paradigm: An Integrated Multivariate Approach to Transdermal Patch System Development

Prajwala S,
Sangeetha G,
Swamivelmanickam M

S P, G S, M S. Quality by Design (QbD) Paradigm: An Integrated Multivariate Approach to Transdermal Patch System Development. J Rep Pharm Sci. 2024;12(1):e146211. doi: https://doi.org/10.5812/jrps.146211

30
Apr
2017
New Product Development in the Pharmaceutical Industry: Evidence from a generic market

New Product Development in the Pharmaceutical Industry: Evidence from a generic market

Nazila Yousefi,
Gholamhossein Mehralian,
Hamid Reza Rasekh,
Mina Yousefi

Yousefi N, Mehralian G, Rasekh HR, Yousefi M. New Product Development in the Pharmaceutical Industry: Evidence from a generic market. Iran J Pharm Res. 2017;16(2):e124989. doi: https://doi.org/10.22037/ijpr.2017.2058

8
Dec
2021
Factors Affecting Innovation Performance in Establishing a Generic Plan in the Pharmaceutical Industry

Factors Affecting Innovation Performance in Establishing a Generic Plan in the Pharmaceutical Industry

Leila Eslami Eshlaghi,
Abbas Khamseh

Eslami Eshlaghi L, Khamseh A. Factors Affecting Innovation Performance in Establishing a Generic Plan in the Pharmaceutical Industry. Shiraz E-Med J. 2022;23(4):e114924. doi: https://doi.org/10.5812/semj.114924

31
Oct
2012

Situation Analysis of R & D Activities: An Empirical Study in Iranian Pharmaceutical Companies

Hamid Reza Rasekh,
Gholamhossein Mehralian,
Abbas Ali Vatankhah-Mohammadabadi

Rasekh HR, Mehralian G, Vatankhah-Mohammadabadi AA. Situation Analysis of R & D Activities: An Empirical Study in Iranian Pharmaceutical Companies. Iran J Pharm Res. 2012;11(4):e125877. doi: https://doi.org/10.22037/ijpr.2012.1192

31
Oct
2016
Distributor– Retailer Interface in Pharmaceutical Supply Chain: Service Quality Measurement Scale

Distributor– Retailer Interface in Pharmaceutical Supply Chain: Service Quality Measurement Scale

Gholamhossein Mehralian,
Jafar Babapour,
farzad peiravian

Mehralian G, Babapour J, peiravian F. Distributor– Retailer Interface in Pharmaceutical Supply Chain: Service Quality Measurement Scale. Iran J Pharm Res. 2016;15(4):e125206. doi: https://doi.org/10.22037/ijpr.2016.1934

More by these authors

Mayur Ashok ChordiyaPubMedScholar
Hemant Hiraman GangurdePubMedScholar
Vikram Nirmal SanchetiPubMedScholar
Share
Cited by
Metrics